ESTRELLA IMMUNOPHARMA, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Notes
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-18
- ESTRELLA IMMUNOPHARMA, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- ESTRELLA IMMUNOPHARMA, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- ESTRELLA IMMUNOPHARMA, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $0.00.
- ESTRELLA IMMUNOPHARMA, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $0.00.
- ESTRELLA IMMUNOPHARMA, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00.
- ESTRELLA IMMUNOPHARMA, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $0.00 derived: sum of 2 quarters · filed 2026-03-18 | $0.00 derived: sum of 3 quarters · filed 2026-03-18 | $0.00 10-K · filed 2026-03-18 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | $0.00 derived: sum of 3 quarters · filed 2025-08-12 | $0.00 derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-14 | $0.00 derived: sum of 2 quarters · filed 2025-05-14 | $0.00 derived: sum of 3 quarters · filed 2025-05-14 | |
| 2024-12-31 | $0.00 derived: 10-KT 6 month − 10-Q 3 month · filed 2025-03-25 | $0.00 10-KT · filed 2025-03-25 | ||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $0.00 10-K · filed 2024-09-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |